Litigation Details for Allergan USA, Inc. v. Aurobindo Pharma Limited (D. Del. 2019)
✉ Email this page to a colleague
Allergan USA, Inc. v. Aurobindo Pharma Limited (D. Del. 2019)
| Docket | ⤷ Start Trial | Date Filed | 2019-12-20 |
| Court | District Court, D. Delaware | Date Terminated | 2022-06-01 |
| Cause | 35:271 Patent Infringement | Assigned To | Richard Gibson Andrews |
| Jury Demand | None | Referred To | |
| Parties | ZYDUS LIFESCIENCES LIMITED | ||
| Patents | 10,960,009; 7,737,142; 7,943,621; RE47,350 | ||
| Attorneys | George J. Barry , III | ||
| Firms | Morris James LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Allergan USA, Inc. v. Aurobindo Pharma Limited
The small molecule drugs covered by the patents cited in this case are ⤷ Start Trial and ⤷ Start Trial .
Details for Allergan USA, Inc. v. Aurobindo Pharma Limited (D. Del. 2019)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2019-12-20 | External link to document | |||
| 2019-12-19 | 1 | Complaint | United States Patent Nos. 7,737,142 (“the ’142 Patent”) and 7,943,621 (“the ’621 Patent”) (collectively…has listed the asserted patents and U.S. Patent No. RE47,350 (“the ’350 Patent”) in the Approved Drug … 1. This action for patent infringement, brought pursuant to the patent laws of the United States…28. This civil action for patent infringement arises under the patent laws of the United States, including… copy of the ’142 Patent is attached as Exhibit A. 61. The ’621 Patent, titled “Salts of | External link to document |
| 2019-12-19 | 104 | Patent/Trademark Report to Commissioner of Patents | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) RE47,350 E . (Dorsney, Kenneth… 2019 1 June 2022 1:19-cv-02317 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
